Researchers at the Perelman School of Medicine at the University of Pennsylvania have for the first time used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul Banerjee, MD discusses the potential mechanism for checkpoint inhibition ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at ...

Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study. PD-1 blockade in combination with bevacizumab and nab-paclitaxel for second-line treatment in ...

Lipid nanoparticle (LNP) mRNA vaccines induce robust immune responses and provide protection against infectious diseases. However, this immunity can be short-lived, resulting in the need for frequent ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...